Alix Ventures

Xilis is an oncology and precision health company focused on cancer diagnosis and treatment using micro-organoids. It develops ex-vivo technologies to accelerate drug discovery and aims to de-risk drug development and guide precision medicine.

Elegen specializes in cell-free clonal gene synthesis through its ENFINIA DNA technology, providing innovative solutions for genetic engineering and synthetic biology.

64x.com offers digital imaging, web hosting, and design services, including posters, banners, and promotional product imprinting.

Mythic is a pioneering AI processor company specializing in analog compute-in-memory technology, which delivers significant improvements in energy efficiency and performance for edge AI applications. Their Analog Matrix Processors enable high-performance computing for various sectors, including automotive, robotics, and defense, while drastically reducing power consumption and costs.

Endpoint Health is a company valued at $150M or more, named in Y Combinator's Top Companies list, and launched to assist hospitals in treating critically ill patients.

Zafrens is pioneering a comprehensive experimental platform that integrates multi-omics and large perturbation libraries to uncover causal relationships in biology. Their technology, Z-Screen, allows for high-throughput experimentation with single-cell resolution, enabling simultaneous phenotypic and molecular screening for drug discovery.

Teiko simplifies cytometry for global clinical trials with innovative products like blood preservation kits and multiparameter flow cytometry services.

Circularis is focused on the cultivation of micro-algae to produce nutritious food and feed ingredients, emphasizing a circular bio-economy and sustainable practices.

Galatea Bio is a biotechnology company focused on leveraging genetic diversity and advanced data analytics to drive innovations in healthcare. They provide clinical testing, genomic services, and biopharma R&D, while emphasizing the importance of underrepresented populations in genetic research.

Basil Systems, also known as basil.bio, focuses on applied AI solutions.

Pair Team is a connected care ecosystem that provides whole-person care by addressing medical, behavioral, and social needs through partnerships with local organizations and AI-enabled technology.

Early-stage TechBio investor focused on platform companies, distinguished by a trademarked TechBio focus and an embedded Fellows program placing MDs, PhDs, and experts as an in-house scientific brain trust. The firm coined and trademarked the term "TechBio" to capture the rise of innovation where technology meets biology. They invest in data-driven life sciences companies that solve problems affecting everyday people from across the globe.

Bioscience investor translating grant-funded research into venture-scale companies, with a pipeline centered on engineering biology using robotic cloud labs and computational design for human health and planetary sustainability. The firm grew directly out of a philanthropic grants program at the Thiel Foundation that funded highly speculative science before spinning into a traditional venture fund.

Flagship Pioneering operates as an "institutional innovation" model that internally originates 80-100 "explorations" per year through Flagship Labs based on "What if…?" hypotheses, then systematically evolves promising ideas through a staged company-creation funnel (Explorations → ProtoCos → NewCos → GrowthCos) that it fully founds, funds, and owns through early stages. The firm positions itself as principal founder rather than a traditional investor, building "bioplatform" companies organized around proprietary discovery engines and operating its own drug development unit, Pioneering Medicines, which partners directly with large pharmas like Pfizer and Novo Nordisk to co-create therapeutics.

Fellowship for early-career scientists run by repeat deep-tech founders, prioritizing technical founder quality, for those who've never written business plans, offering up to $1M and not taking IP rights. SciFounders is run by repeat deep-tech founders who previously built Mammoth Biosciences and Conception. The fund is designed for scientists who have never written a business plan and focuses on technical founder quality over trendy ideas, operating as a long-term partner rather than a fixed-cohort program with no formal end date.

Early-stage accelerator for synthetic biology and life sciences that gives scientist-founders lab independence with co-located BSL-rated wet labs and extended runway via SOSV integration reserving 75% for follow-ons. The world's first startup accelerator focused specifically on synthetic biology and life sciences, created to give scientists independence as founders rather than forcing them into traditional academic or big-pharma tracks. The program runs its own large wet-lab infrastructure where portfolio companies co-locate and build in BSL-rated labs owned by the fund, while providing an unusually long runway of capital through deep integration with SOSV's fund structure that reserves 75% for follow-on rounds.